Healthcare / Medical Instruments & SuppliesNasdaqCM
$1.25
+0.01 (+0.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-69.0M · quality 67.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$14M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-59.4%
↓Gross Margin
46.3%
↓Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
+14.7%
FCF CAGR
—
FCF margin
-57.3%
FCF / Net income
0.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $28.5M · net income $-26.4M · FCF $-16.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $28.5M | $28.5M | $30.8M | $36.1M | $27.8M | $18.0M | $8.5M | $10.1M | $12.0M | $9.5M |
| Net Income | $-26.4M | $-26.4M | $-112.0M | $-232.5M | $-132.6M | $-72.4M | $-41.1M | $-29.8M | $-18.5M | $-23.4M |
| EBITDA | $-16.3M | $-16.3M | $-95.4M | $-221.5M | $-120.6M | $-73.8M | $-37.1M | $-24.7M | $-19.1M | $-21.7M |
| EPS | -4.85 | -4.85 | -60.05 | -408.60 | -267.71 | -156.00 | — | — | — | — |
| Gross Margin | 46.3% | 46.3% | 1.2% | 26.5% | 21.4% | — | — | — | — | — |
| Operating Margin | -116.9% | -116.9% | -247.8% | -380.0% | -473.7% | -428.8% | -453.4% | -255.4% | -170.1% | -244.3% |
| Net Margin | -92.6% | -92.6% | -364.0% | -643.7% | -476.9% | -402.8% | -483.4% | -294.3% | -154.1% | -245.8% |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.16 | 0.16 | 0.20 | 0.10 | 0.05 | 0.00 | 0.47 | 0.00 | 0.89 | 0.00 |
| Current Ratio | 1.84 | 1.84 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-16.3M | $-16.3M | $-69.0M | $-126.9M | $-128.1M | — | $-38.3M | $-29.6M | $-20.3M | $-21.8M |
| Returns | ||||||||||
| ROE | -59.4% | -59.4% | -316.7% | -241.8% | -53.2% | -21.5% | -117.2% | -825.2% | -182.5% | 46.5% |
| Valuation | ||||||||||
| P/B | 0.15 | 0.15 | 1.01 | 0.59 | 1.74 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | -7.4% | -7.4% | -14.8% | 29.9% | — | 111.5% | -16.1% | -15.6% | 26.3% | — |
| EPS Growth | 91.9% | 91.9% | 85.3% | -52.6% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-65.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-60.05 → -4.85
Residual
-65.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.